Lilly’s Olumiant is first JAK drug backed by NICE for eczemaEli Lilly’s JAK inhibitor Olumiant has become the first drug in the JAK inhibitor class to be recommended Share XLilly’s Olumiant is first JAK drug backed by NICE for eczemahttps://pharmaphorum.com/news/lillys-olumiant-is-first-jak-drug-backed-by-nice-for-eczema/
Almirall names Nazzi as new CEO after Guenter leaves for MerckSpanish drugmaker Almirall has lined up its new CEO following the departure of Peter Guenter, who left to Share XAlmirall names Nazzi as new CEO after Guenter leaves for Merckhttps://pharmaphorum.com/news/almirall-names-nazzi-as-new-ceo-after-guenter-leaves-for-merck/
Almirall, Happify partner on digital tool for psoriasis mental healthIt’s well recognised that people with psoriasis can develop depression or anxiety, particularly in moderate or severe cases Share XAlmirall, Happify partner on digital tool for psoriasis mental healthhttps://pharmaphorum.com/news/almirall-happify-partner-on-digital-tool-for-psoriasis-mental-health/
Popit and Almirall’s new app tracks adherence to psoriasis medFinnish startup Popit has joined with Spain’s Almirall to produce an app that tracks whether patients have taken Share XPopit and Almirall’s new app tracks adherence to psoriasis medhttps://pharmaphorum.com/news/popit-and-almiralls-new-app-tracks-adherence-to-psoriasis-med/
FDA sets April verdict for Pfizer’s “underestimated” atopic dermatitis drugPfizer could be just a few months away from getting FDA approval for its JAK1 inhibitor abrocitinib in Share XFDA sets April verdict for Pfizer’s “underestimated” atopic dermatitis drughttps://pharmaphorum.com/news/fda-sets-april-verdict-for-pfizers-underestimated-atopic-dermatitis-drug/
FDA hands Cassiopea its first approval, for acne drug WinleviItalian biotech Cassiopea has won US approval for Winlevi, a topical therapy it says is the first new Share XFDA hands Cassiopea its first approval, for acne drug Winlevihttps://pharmaphorum.com/news/fda-hands-cassiopea-its-first-approval-for-acne-drug-winlevi/
UCB’s IL-17 latecomer bimekizumab beats Cosentyx in psoriasis trialBelgian biopharma company UCB is bringing up the rear of the IL-17 inhibitor category with its bimekizumab drug, Share XUCB’s IL-17 latecomer bimekizumab beats Cosentyx in psoriasis trialhttps://pharmaphorum.com/news/ucbs-il-17-latecomer-bimekizumab-beats-cosentyx-in-psoriasis-trial/
Novartis takes $485m hit after axing eczema drug from pipelineNovartis has axed development of its mid-stage eczema drug ZPL389, taking a $485 million hit in the process. Share XNovartis takes $485m hit after axing eczema drug from pipelinehttps://pharmaphorum.com/news/novartis-takes-485m-hit-after-axing-eczema-drug-from-pipeline/
LEO eyeing 2021 US launch for eczema drug tralokinumabLEO Pharma is gearing up to launch its eczema drug tralokinumab next year after submitting a filing to the Share XLEO eyeing 2021 US launch for eczema drug tralokinumabhttps://pharmaphorum.com/news/leo-eyeing-2021-us-launch-for-eczema-drug-tralokinumab/
